01—Abstract
Summary
Summary of the 10-K filed February 23, 2023. Cited figures are marked; the original filing is the authoritative source.
Guardant Health, Inc. (GH) presented its 2022 Form 10-K filing, highlighting significant revenue growth driven by its precision oncology testing services, which increased by 29% year-over-year to $392 milliona.
Despite this growth, the company continues to incur substantial net losses, with a reported net loss of $654.6 millionb for the year, indicating ongoing investments in research and development and commercial expansion. The company's core strategy revolves around expanding the clinical utility and reimbursement of its liquid biopsy tests across all cancer stages, from early detection to recurrence monitoring.
Key product launches and study results, such as the positive efficacy data from the ECLIPSE study for its Shield blood test for colorectal cancer screening, underscore the company's commitment to innovation. However, significant risks remain, including continued operational losses, intense competition, and ongoing regulatory scrutiny, particularly concerning laboratory-developed tests (LDTs) and reimbursement policies from third-party payers.
02—Key points
Key Highlights
- Total revenue increased by 20% to $449.5 million in 2022, primarily driven by a 29% increase in precision oncology testing revenue to $392.0 million.
- The company reported a net loss of $654.6 million for the year ended December 31, 2022, compared to a net loss of $384.8 million in 2021, reflecting significant R&D and sales & marketing investments.
- Guardant360 CDx test, a companion diagnostic, received FDA approval for use with specific therapies in non-small cell lung cancer and breast cancer, expanding its commercial utility.
- Positive results were announced for the Shield LDT test for colorectal cancer screening, with an 83% sensitivity in detecting colorectal cancer in the ECLIPSE study, leading to plans for an FDA PMA submission.
- Research and development expenses increased by 42% to $373.8 million, and sales and marketing expenses grew by 56% to $299.8 million, highlighting continued investment in product development and market expansion.
- The company ended the year with $1.0 billion in cash, cash equivalents, and marketable debt securities, providing a substantial liquidity buffer, though continued losses necessitate careful capital management.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 23, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $449.54M$373.65M | +20.3% |
| R&D Expenses | $373.81M$263.22M | +42.0% |
| Operating Expenses | $993.92M$784.65M | +26.7% |
| Operating Income | -$544.38M-$411.00M | −32.5% |
| Interest Expense | $2.58M$2.58M | 0.0% |
| Net Income | -$654.59M-$405.67M | −61.4% |
| EPS (Basic) | $-6.41$-4.00 | −60.2% |
| EPS (Diluted) | $-6.41$-4.00 | −60.2% |
| Shares Outstanding (Basic) | 102.18M101.31M | +0.9% |
| Shares Outstanding (Diluted) | 102.18M101.31M | +0.9% |
05—Questions
Frequently Asked Questions
What is Guardant Health's current financial standing?
Guardant Health generated $449.5 million in total revenue for the year ended December 31, 2022, a 20% increase from the prior year. However, the company reported a net loss of $654.6 million for the same period. Despite significant revenue growth, the company is not yet profitable and continues to invest heavily in research, development, and commercialization efforts.
What are the key products and growth drivers for Guardant Health?
Guardant Health's primary revenue driver is its precision oncology testing, including the Guardant360 suite of tests for advanced-stage cancer patients. The company is also focused on expanding into early cancer detection and recurrence monitoring with products like Shield and Guardant Reveal. Collaborations with biopharmaceutical companies for companion diagnostics and clinical studies are also significant.
What are the major risks and challenges facing Guardant Health?
Key risks include the company's ongoing net losses and its ability to achieve profitability, dependence on payer coverage and reimbursement for its tests, intense competition in the precision oncology market, lengthy and complex new product development cycles, and the evolving regulatory landscape for diagnostic tests, particularly laboratory-developed tests (LDTs).
What progress has Guardant Health made in cancer screening?
Guardant Health launched its Shield LDT test for colorectal cancer screening in May 2022 and announced positive results from the ECLIPSE study, demonstrating 83% sensitivity in detecting colorectal cancer. The company plans to submit a PMA to the FDA for this test and is also investigating its next-generation Shield assay for lung and multi-cancer screening.
06—Continue